| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Editorial Board
|
|
|
|
32 |
S3 |
p. i
|
artikel
|
| 2 |
LBA-4 Initial data from the phase 3 KEYNOTE-811 study of trastuzumab and chemotherapy with or without pembrolizumab for HER2-positive metastatic gastric or gastroesophageal junction (G/GEJ) cancer
|
Janjigian, Y.
|
|
|
32 |
S3 |
p. S227
|
artikel
|
| 3 |
LBA-3 Integrated analysis of cell-free DNA (cfDNA) BRAF mutant allele fraction (MAF) and whole exome sequencing in BRAFV600E metastatic colorectal cancer (mCRC) treated with BRAF-antiEGFR +/- MEK inhibitors
|
Élez, E.
|
|
|
32 |
S3 |
p. S226-S227
|
artikel
|
| 4 |
LBA-1 Phase 3 APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) vs gemcitabine (Gem) alone in patients with resected pancreatic cancer (PC): Updated 5-year overall survival
|
Tempero, M.
|
|
|
32 |
S3 |
p. S226
|
artikel
|
| 5 |
LBA-5 Phase Ib study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic esophageal cancer
|
Wainberg, Z.
|
|
|
32 |
S3 |
p. S227-S228
|
artikel
|
| 6 |
LBA P-298 Response to total neoadjuvant therapy and survival in patients with early onset locally advanced rectal cancer
|
Lumish, M.
|
|
|
32 |
S3 |
p. S228
|
artikel
|
| 7 |
O-10 ANCHOR CRC: Results from a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E–mutant metastatic colorectal cancer
|
Van Cutsem, E.
|
|
|
32 |
S3 |
p. S222
|
artikel
|
| 8 |
O-4 Average cumulative relative dose of adjuvant chemotherapy is more important than average relative dose intensity for colorectal cancer survival, with implications for treating obese patients: The OCTOPUS consortium
|
Slawinski, C.
|
|
|
32 |
S3 |
p. S218-S219
|
artikel
|
| 9 |
O-3 Characterization of KRAS mutation variants and prevalence of KRAS-G12C in gastrointestinal malignancies
|
Salem, M.
|
|
|
32 |
S3 |
p. S218
|
artikel
|
| 10 |
O-14 Exploratory biomarker analysis of trastuzumab deruxtecan in DESTINY-Gastric01, a randomized, phase 2, multicenter, open-label study in patients with HER2-positive or -low advanced gastric or gastroesophageal junction adenocarcinoma
|
Shitara, K.
|
|
|
32 |
S3 |
p. S224
|
artikel
|
| 11 |
O-8 Final overall survival for the phase 3 KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer
|
André, T.
|
|
|
32 |
S3 |
p. S220-S221
|
artikel
|
| 12 |
O-7 FOLFIRI ± napabucasin in patients with previously treated metastatic colorectal cancer: Overall survival results from the phase 3 CanStem303C study
|
Shah, M.
|
|
|
32 |
S3 |
p. S220
|
artikel
|
| 13 |
O-5 Frequency of minimal residual disease as measured by ctDNA in mismatch repair deficient tumors following curative resection
|
Janjigian, Y.
|
|
|
32 |
S3 |
p. S219
|
artikel
|
| 14 |
O-9 5-FU/LV + cetuximab + vemurafenib as maintenance therapy for BRAF-mutant (BRAFmut) metastatic colorectal cancer: Efficacy, safety, and exploratory biomarker findings from Cohort 1 of the MODUL trial
|
Ducreux, M.
|
|
|
32 |
S3 |
p. S221-S222
|
artikel
|
| 15 |
O-6 Gene alterations in ctDNA related to the resistance mechanism of anti-EGFR antibodies and clinical efficacy outcomes of anti-EGFR antibody rechallenge plus trifluridine/tipiracil in metastatic colorectal cancer patients in WJOG8916G trial
|
Takahashi, N.
|
|
|
32 |
S3 |
p. S219-S220
|
artikel
|
| 16 |
O-13 Gut microbiome to predict survival time in advanced gastric cancer treated with nivolumab: The DELIVER trial (JACCRO GC-08)
|
Sunakawa, Y.
|
|
|
32 |
S3 |
p. S223-S224
|
artikel
|
| 17 |
O-16 HEPANOVA: Final efficacy and safety results from a phase 2 study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with sorafenib in advanced hepatocellular carcinoma
|
Gkika, E.
|
|
|
32 |
S3 |
p. S225
|
artikel
|
| 18 |
O-11 Monitoring molecular residual disease by circulating tumor DNA in resectable colorectal cancer: Molecular subgroup analyses of a prospective observational study GALAXY in CIRCULATE-Japan
|
Shirasu, H.
|
|
|
32 |
S3 |
p. S222-S223
|
artikel
|
| 19 |
O-2 Overall survival and long-term safety data from the NETTER-1 trial: 177-Lu-Dotatate vs. high-dose octreotide in patients with progressive midgut NETs
|
Strosberg, J.
|
|
|
32 |
S3 |
p. S217-S218
|
artikel
|
| 20 |
O-12 Phase II study of preoperative chemoradiotherapy plus avelumab in patients with locally advanced rectal cancer: The AVANA study
|
Salvatore, L.
|
|
|
32 |
S3 |
p. S223
|
artikel
|
| 21 |
O-15 Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302) in the overall population and Europe/North America subgroup
|
Ajani, J.
|
|
|
32 |
S3 |
p. S225
|
artikel
|
| 22 |
O-1 Results from a global phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with unresectable hepatocellular carcinoma
|
Ducreux, M.
|
|
|
32 |
S3 |
p. S217
|
artikel
|
| 23 |
P-144 A comparative analysis of secondary data from the ToGA and EVIDENCE studies on the effectiveness of trastuzumab plus chemotherapy in Asian patients with HER2+ metastatic gastric cancer
|
Shen, L.
|
|
|
32 |
S3 |
p. S148
|
artikel
|
| 24 |
P-269 Advanced gastric cancer bleeding: Association of hemostatic radiotherapy and iron supplementation - Is there a survival benefit?
|
Laranja, A.
|
|
|
32 |
S3 |
p. S189
|
artikel
|
| 25 |
P-156 A European chart review of treatment patterns and outcomes for patients with resected esophageal cancer or gastroesophageal junction cancer
|
Singh, P.
|
|
|
32 |
S3 |
p. S152-S153
|
artikel
|
| 26 |
P-56 A multicenter prospective translational study using circulating tumor DNA to identify acquired genomic alterations in recurrent gastric or gastroesophageal junction adenocarcinoma in patients who received curative-intent treatment (Liquid-GEAR)
|
Takeda, H.
|
|
|
32 |
S3 |
p. S115-S116
|
artikel
|
| 27 |
P-176 A multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin with or without CPI-613 as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-04)
|
Sahai, V.
|
|
|
32 |
S3 |
p. S160
|
artikel
|
| 28 |
P-182 A multicenter study of prognostic factors in nivolumab monotherapy for advanced or recurrent esophageal cancer
|
Ikoma, T.
|
|
|
32 |
S3 |
p. S162
|
artikel
|
| 29 |
P-19 A multicentred phase II clinical trial on yttrium 90-resin microspheres followed by gemcitabine-cisplatin for treatment of locally advanced intra-hepatic cholangiocarcinoma
|
Chan, S.
|
|
|
32 |
S3 |
p. S102
|
artikel
|
| 30 |
P-96 Analysis of three biographical times of disease in the IMbrave 150 study: A new measure to assess clinical effect
|
Ceballos Barbancho, E.
|
|
|
32 |
S3 |
p. S130
|
artikel
|
| 31 |
P-45 An open-label, phase 2 study of patritumab deruxtecan in patients with previously treated advanced/metastatic colorectal cancer
|
Raghav, K.
|
|
|
32 |
S3 |
p. S111
|
artikel
|
| 32 |
P-72 A patient preference study on risk thresholds to switch between daily tablets and biweekly infusions in second-line treatment for advanced hepatocellular carcinoma
|
Parikh, N.
|
|
|
32 |
S3 |
p. S121-S122
|
artikel
|
| 33 |
P-200 A phase II study of dose reductive XELOX plus bevacizumab in elderly or vulnerable patients with metastatic colorectal cancer: MCSGO-1202
|
Nakata, K.
|
|
|
32 |
S3 |
p. S168
|
artikel
|
| 34 |
P-100 A phase II study of first-line chemotherapy initiating FOLFIRI+cetuximab and switching to FOLFIRI+bevacizumab according to early tumor shrinkage at 8 weeks in RAS wild-type metastatic colorectal cancer: HYBRID trial
|
Shoji, H.
|
|
|
32 |
S3 |
p. S132
|
artikel
|
| 35 |
P-140 A phase I study of biweekly abraxane in combination with oxaliplatin and oral S-1/leucovorin as first line treatment for advanced gastric, pancreatic and biliary tract cancers
|
Tsai, H.
|
|
|
32 |
S3 |
p. S146-S147
|
artikel
|
| 36 |
P-155 A phase I study of FLOT as first-line therapy for Japanese patients with advanced gastric cancer including patients with or without severe peritoneal metastasis
|
Shiraishi, K.
|
|
|
32 |
S3 |
p. S152
|
artikel
|
| 37 |
P-139 A phase 2 multicohort study (LEAP-005) of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors: Pancreatic cancer cohort
|
Chung, H.
|
|
|
32 |
S3 |
p. S146
|
artikel
|
| 38 |
P-24 A prospective phase 1b dose de-escalation open-label clinical study to evaluate the safety and efficacy of sorafenib with metformin and atorvastatin in advanced hepatocellular carcinoma (SMASH)
|
Bhargava, P.
|
|
|
32 |
S3 |
p. S104
|
artikel
|
| 39 |
P-185 A prospective, randomized, controlled, multicenter phase III clinical trial of apatinib combined with neoadjuvant chemoradiotherapy for patients with locally advanced, HER2-negative, Siewert’s type II-III adenocarcinoma of esophagogastric junction
|
Zhao, Q.
|
|
|
32 |
S3 |
p. S163
|
artikel
|
| 40 |
P-243 A prospective study to assess the impact of colostomy on psychosocial aspects of quality of life in colorectal cancer patients
|
Khosla, D.
|
|
|
32 |
S3 |
p. S181-S182
|
artikel
|
| 41 |
P-154 A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy compared with chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015
|
Tabernero, J.
|
|
|
32 |
S3 |
p. S151-S152
|
artikel
|
| 42 |
P-25 A review of circulating exosomal biomarkers in the diagnosis of pancreatic cancer
|
Sha, M.
|
|
|
32 |
S3 |
p. S104
|
artikel
|
| 43 |
P-98 A single-arm study of apatinib plus neoadjuvant chemotherapy followed by resection in patients with locally advanced colorectal adenocarcinoma
|
Zhang, T.
|
|
|
32 |
S3 |
p. S131
|
artikel
|
| 44 |
P-157 Assessing fitness for systemic therapy in hepatocellular carcinoma: Evaluating time on treatment according to Child-Pugh classification, model for end-stage liver disease score, and AFP level
|
Staum, B.
|
|
|
32 |
S3 |
p. S153
|
artikel
|
| 45 |
P-170 Assessment of long-term outcomes and predictive factors of malignancy in branch-duct intraductal papillary mucinous neoplasms: A retrospective study in a Canadian referral center
|
Chennouf, A.
|
|
|
32 |
S3 |
p. S157-S158
|
artikel
|
| 46 |
P-286 Assessment of the quality of life of patients with colorectal cancer in the Tunisian Center: A report of 142 patients
|
Ben Moussa, C.
|
|
|
32 |
S3 |
p. S194
|
artikel
|
| 47 |
P-103 Associations between quality-of-life, symptom burden, and demographic characteristics in long-term esophageal and gastroesophageal junction cancer survivors
|
McGillivray, E.
|
|
|
32 |
S3 |
p. S133
|
artikel
|
| 48 |
P-126 Atezolizumab plus bevacizumab for patients with advanced hepatocellular carcinoma and chronic hepatitis B virus infection with high viral load
|
Chen, S.
|
|
|
32 |
S3 |
p. S141-S142
|
artikel
|
| 49 |
P-51 Baseline characteristics of patients enrolled in the CAPSTAN study: A European retrospective study in BRAFV600E-mutant metastatic colorectal cancer patients
|
Martinelli, E.
|
|
|
32 |
S3 |
p. S113
|
artikel
|
| 50 |
P-199 Baseline neutrophil to lymphocyte ratio predicts survival in patients with metastatic colorectal cancer treated with cetuximab plus avelumab (CAVE) as a rechallenge strategy
|
Ciardiello, D.
|
|
|
32 |
S3 |
p. S167-S168
|
artikel
|
| 51 |
P-259 Bone scan in gastrointestinal cancer
|
Ghomari, C.
|
|
|
32 |
S3 |
p. S186
|
artikel
|
| 52 |
P-209 Cancers of the bile duct: A study of 30 cases
|
Benamar, W.
|
|
|
32 |
S3 |
p. S170
|
artikel
|
| 53 |
P-210 Capecitabine and temozolomide for metastatic neuroendocrine neoplasms: A single-center “real-word” data analysis
|
Caetano, A.
|
|
|
32 |
S3 |
p. S171
|
artikel
|
| 54 |
P-125 Caring for more than survival: A survey of patient preferences in advanced hepatocellular carcinoma
|
Sharma, R.
|
|
|
32 |
S3 |
p. S141
|
artikel
|
| 55 |
P-278 Checkpoint inhibitors in patients with advanced, refractory biliary tract cancers
|
Liddell, S.
|
|
|
32 |
S3 |
p. S192
|
artikel
|
| 56 |
P-192 Chemoradiation for anal canal carcinoma: A multicentric retrospective cohort study
|
Leão, I.
|
|
|
32 |
S3 |
p. S165
|
artikel
|
| 57 |
P-99 Circulating RNA detection, circulating tumor cells count, and molecular tumor profiling in a cohort of untreated metastatic colorectal cancer: A prospective multicenter ancillary study to the randomized VISNÚ trials
|
Valladares-Ayerbes, M.
|
|
|
32 |
S3 |
p. S131-S132
|
artikel
|
| 58 |
P-108 Circulating tumor DNA for early relapse detection and monitoring disease status in patients with early-stage pancreatic adenocarcinoma
|
Abdelrahim, M.
|
|
|
32 |
S3 |
p. S135
|
artikel
|
| 59 |
P-114 Claudin 18 isoform expression in gastric adenocarcinoma and pancreatic adenocarcinoma
|
Saito, T.
|
|
|
32 |
S3 |
p. S138
|
artikel
|
| 60 |
P-237 Clinical doctors’ attitudes towards colorectal cancer genetic testing: A national multi-center cross-sectional study
|
Liu, Y.
|
|
|
32 |
S3 |
p. S179-S180
|
artikel
|
| 61 |
P-258 Clinical study of PD-1 disrupted anti-MUC1 CAR-T cells in patients with advanced oesophageal cancer
|
Chen, S.
|
|
|
32 |
S3 |
p. S186
|
artikel
|
| 62 |
P-146 Clinical usefulness of next generation sequencing by liquid biopsy for advanced gastric cancer
|
Matsumoto, T.
|
|
|
32 |
S3 |
p. S149
|
artikel
|
| 63 |
P-225 Clinico-epidemiological and therapeutic profile of rectal cancer: Experience of the department of radiation oncology EHSO ORAN
|
Cheriguene, M.
|
|
|
32 |
S3 |
p. S176
|
artikel
|
| 64 |
P-238 Clinicopathological profile and prognostic factors impacting survival of periampullary carcinoma: A tertiary care centre experience
|
Singla, A.
|
|
|
32 |
S3 |
p. S180
|
artikel
|
| 65 |
P-90 Combined high expression of MAP17 and fascin-1 in colorectal cancer: Targeted therapy in need?
|
Tampakis, A.
|
|
|
32 |
S3 |
p. S128
|
artikel
|
| 66 |
P-227 Comparative safety and tolerability of approved PARP inhibitors in cancer: A systematic review and network meta-analysis
|
Cai, Z.
|
|
|
32 |
S3 |
p. S176-S177
|
artikel
|
| 67 |
P-165 Comparative study on the clinical effect of hand-assisted laparoscopic and laparoscopic gastrectomy for gastric stromal tumor
|
Zhang, Q.
|
|
|
32 |
S3 |
p. S156
|
artikel
|
| 68 |
P-246 Comparison of microbiome diversity in gastric cancer patients and in non-cancerous patients
|
Bang, E.
|
|
|
32 |
S3 |
p. S182-S183
|
artikel
|
| 69 |
P-112 Compliance analysis of biological samples and questionnaire collection in a colorectal cancer microbiome study: The VHIO experience
|
Napoli, S.
|
|
|
32 |
S3 |
p. S137
|
artikel
|
| 70 |
P-179 Complications of the rescue esophagectomy in advanced esophageal cancer
|
Braga de Aquino, J.
|
|
|
32 |
S3 |
p. S161
|
artikel
|
| 71 |
P-242 Comprehensive assessment of systemic and local immunity and clinical indicators in patients with gastric cancer
|
Khakimova, G.
|
|
|
32 |
S3 |
p. S181
|
artikel
|
| 72 |
P-129 Concomitant RAS and BRAF mutations: Impact on overall survival and progression free survival in metastatic colorectal cancer patients
|
Pretta, A.
|
|
|
32 |
S3 |
p. S142-S143
|
artikel
|
| 73 |
P-20 Concurrent chemo-radiotherapy in anal squamous cell carcinomas: A 10-year retrospective review of a tertiary centre experience
|
Elmasry, A.
|
|
|
32 |
S3 |
p. S102-S103
|
artikel
|
| 74 |
P-239 Consensus molecular subtypes of morphological regions on colorectal tumors
|
Popovici, V.
|
|
|
32 |
S3 |
p. S180
|
artikel
|
| 75 |
P-55 Constructing hybrid control for the Morpheus metastatic colorectal cancer trial using IMblaze370 historical trial data
|
Li, C.
|
|
|
32 |
S3 |
p. S115
|
artikel
|
| 76 |
P-43 C677T and A1298C MTHFR gene polymorphisms and response to fluoropyrimidine-based chemotherapy in mestizo patients with metastatic colorectal cancer
|
Ramos-Esquivel, A.
|
|
|
32 |
S3 |
p. S110
|
artikel
|
| 77 |
P-17 CT colonography: A minimally invasive screening option for colorectal cancer
|
Grewal, J.
|
|
|
32 |
S3 |
p. S101
|
artikel
|
| 78 |
P-173 Customisation of therapeutic strategy in metastatic colorectal cancer by use of liquid biopsies: Final results of an observational study
|
Kastrisiou, M.
|
|
|
32 |
S3 |
p. S158-S159
|
artikel
|
| 79 |
P-109 CYTOFLOC: Evaluation of a non-endoscopic immunocytological device (Cytosponge™) for post-chemo-radiotherapy surveillance in patients with oesophageal cancer – a feasibility study
|
Mukherjee, S.
|
|
|
32 |
S3 |
p. S135-S136
|
artikel
|
| 80 |
PD-4 A phase I trial of trifluridine/tipiracil in combination with nanoliposomal irinotecan in advanced GI cancers
|
Alese, O.
|
|
|
32 |
S3 |
p. S200
|
artikel
|
| 81 |
P-158 Deciphering the immunological determinants of response to neoadjuvant chemo-radiation in esophageal adenocarcinoma
|
Arbore, G.
|
|
|
32 |
S3 |
p. S153
|
artikel
|
| 82 |
P-107 Dermatopathological review of cutaneous squamous cell carcinoma events in patients with gastrointestinal stromal tumors treated with ripretinib
|
Patel, A.
|
|
|
32 |
S3 |
p. S134-S135
|
artikel
|
| 83 |
P-106 Descriptive study of long-term survivors with advanced pancreatic cancer
|
Aviñó Tarazona, V.
|
|
|
32 |
S3 |
p. S134
|
artikel
|
| 84 |
P-136 Detecting panitumumab/FOLFOX responders in K-Ras wild-type metastatic colorectal cancer through an artificial intelligence-based analytical tool
|
Galmarini, C.
|
|
|
32 |
S3 |
p. S145
|
artikel
|
| 85 |
P-253 Detection of potential molecules that might be implicated in colorectal metastasis to lung
|
Apostolou, P.
|
|
|
32 |
S3 |
p. S184
|
artikel
|
| 86 |
P-236 Determination of PD-L1 and MSI in ampullary carcinomas
|
Eremeeva, E.
|
|
|
32 |
S3 |
p. S179
|
artikel
|
| 87 |
P-248 Determination of the optimal electrical field for apoptosis in the rat stomach during irreversible electroporation
|
Park, G.
|
|
|
32 |
S3 |
p. S183
|
artikel
|
| 88 |
P-277 Development of an immune-related gene prognostic index for esophageal squamous cell carcinoma
|
Ji, Q.
|
|
|
32 |
S3 |
p. S192
|
artikel
|
| 89 |
PD-2 Final result of phase IB study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer
|
Kim, R.
|
|
|
32 |
S3 |
p. S199
|
artikel
|
| 90 |
P-15 Diagnostic potential of erythrocyte and serum fatty acids in spotting adenomatous polyps and identifying the early stages of colorectal cancer depending on tumor localization
|
Kruchinina, M.
|
|
|
32 |
S3 |
p. S101
|
artikel
|
| 91 |
P-168 Differences in coping strategies used by colorectal vs. non-colorectal cancer patients: Data from the Neoetic-SEOM study
|
Pacheco-Barcia, V.
|
|
|
32 |
S3 |
p. S157
|
artikel
|
| 92 |
P-222 Dihydropyrimidine dehydrogenase deficiencies and fluoropyrimidine toxicities: A study in the Tunisian Center
|
Melliti, R.
|
|
|
32 |
S3 |
p. S175
|
artikel
|
| 93 |
PD-3 Impact of RAS status, prior targeted therapy, age, and gender on the activity of aflibercept plus FOLFIRI in patients with metastatic colorectal cancer: Real-world data from the QoLiTrap study
|
von Moos, R.
|
|
|
32 |
S3 |
p. S199-S200
|
artikel
|
| 94 |
PD-1 MOUNTAINEER: Open-label, phase 2 study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress)
|
Siena, S.
|
|
|
32 |
S3 |
p. S199
|
artikel
|
| 95 |
P-171 Does metastasectomy really improve survival in gastric cancer?
|
Moura, F.
|
|
|
32 |
S3 |
p. S158
|
artikel
|
| 96 |
P-145 Doublet regimen plus anti-vascular endothelial growth factor drug regimen after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer
|
Matsumoto, T.
|
|
|
32 |
S3 |
p. S148-S149
|
artikel
|
| 97 |
P-60 Doxycycline as preventive treatment of skin toxicity in patients with metastatic colorectal cancer treated with an anti-EGFR and chemotherapy
|
Ramirez Daffos, P.
|
|
|
32 |
S3 |
p. S117
|
artikel
|
| 98 |
PD-6 Prediction of patients at high risk of upper gastrointestinal cancer for endoscopy using artificial intelligent technology
|
Lin, Y.
|
|
|
32 |
S3 |
p. S201
|
artikel
|
| 99 |
PD-5 Retrospective comparative analysis of K-ras G12C vs other K-ras mutations in metastatic colorectal cancer patients treated with first-line chemotherapy doublet + bevacizumab
|
Giampieri, R.
|
|
|
32 |
S3 |
p. S200
|
artikel
|
| 100 |
P-177 Early onset colorectal cancer outcomes in a public Uruguayan cancer centre
|
Fontes, S.
|
|
|
32 |
S3 |
p. S160
|
artikel
|
| 101 |
P-175 Effectiveness, prognostic factors and safety concerning ablative techniques in liver metastases from gastrointestinal tumors
|
Gomez-Randulfe Rodriguez, M.
|
|
|
32 |
S3 |
p. S159-S160
|
artikel
|
| 102 |
P-76 Effect of educational activity on the knowledge of oncologists regarding the latest clinical trial data investigating immunotherapy combination regimens for the frontline treatment of patients with unresectable HCC
|
Dorkhom, N.
|
|
|
32 |
S3 |
p. S123
|
artikel
|
| 103 |
P-121 Efficacy and toxicity of biosimilar and original bevacizumab in the second-line treatment of metastatic colon cancer in routine clinical practice: Results of an observational multicenter study
|
Fedyanin, M.
|
|
|
32 |
S3 |
p. S140
|
artikel
|
| 104 |
P-13 Efficacy of FOLFOX4 regimen with advanced hepatocellular carcinoma and prognostic factors for survival
|
Chayangsu, C.
|
|
|
32 |
S3 |
p. S100
|
artikel
|
| 105 |
P-167 Efficacy of PD-1 inhibitors for colorectal cancer and polyps in Lynch syndrome patients
|
Xiao, B.
|
|
|
32 |
S3 |
p. S156
|
artikel
|
| 106 |
P-235 E-health monitoring during pancreatic cancer treatment
|
Jorge, T.
|
|
|
32 |
S3 |
p. S179
|
artikel
|
| 107 |
P-58 Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma: A multi-centric, multi-national, prospective, longitudinal, non-interventional study in Germany and Austria – BERING CRC
|
Stintzing, S.
|
|
|
32 |
S3 |
p. S116
|
artikel
|
| 108 |
P-250 Epidemiological, diagnostic and therapeutic profile of pancreatic cancer: Experience of a medical oncology department
|
Chaibdra Tani, S.
|
|
|
32 |
S3 |
p. S183-S184
|
artikel
|
| 109 |
P-147 Epigenetic gene somatic mutations in gastric cancer
|
Kalinkin, A.
|
|
|
32 |
S3 |
p. S149
|
artikel
|
| 110 |
P-296 Establishment of adoptive cell therapy with tumor-infiltrating lymphocytes for liver and oesophageal cancer
|
Ma, S.
|
|
|
32 |
S3 |
p. S197-S198
|
artikel
|
| 111 |
P-245 Evaluation of colon-specific plasma nanovesicles as new markers of colorectal cancer
|
Nazarova, I.
|
|
|
32 |
S3 |
p. S182
|
artikel
|
| 112 |
P-275 Evaluation of radical chemoradiation outcomes in stage II/III anal cancer: Real-world data population
|
Fernandes, I.
|
|
|
32 |
S3 |
p. S191
|
artikel
|
| 113 |
P-95 EV-202: An open-label, multicenter, phase 2 study of enfortumab vedotin in patients with previously treated locally advanced or metastatic solid tumors, including upper gastrointestinal cancers
|
Muro, K.
|
|
|
32 |
S3 |
p. S130
|
artikel
|
| 114 |
P-66 Experience in our center of bone events not related to the disease in patients with locally advanced or metastatic adenocarcinoma of the pancreas
|
Gallego Jimenez, I.
|
|
|
32 |
S3 |
p. S119
|
artikel
|
| 115 |
P-23 Experience of concurrent chemoradiotherapy for pancreatic cancer in a large university hospital
|
Searle, G.
|
|
|
32 |
S3 |
p. S104
|
artikel
|
| 116 |
P-28 Exploratory analysis of patients with gastric/GEJ adenocarcinoma with or without liver metastasis from the phase 3 RAINBOW study
|
Ogata, T.
|
|
|
32 |
S3 |
p. S105-S106
|
artikel
|
| 117 |
P-274 Exploratory analysis of potential clinical, molecular and analytical prognostic factors of real-world patients with gastrointestinal stromal tumors: A single center study
|
Perez Criado, I.
|
|
|
32 |
S3 |
p. S191
|
artikel
|
| 118 |
P-284 Exploratory magnetic resonance imaging histogram biomarkers for response prediction to neoadjuvant treatment in oesophageal/gastro-oesophageal cancer
|
Owczarczyk, K.
|
|
|
32 |
S3 |
p. S193-S194
|
artikel
|
| 119 |
P-181 Exploratory randomized phase II trial for optimizing treatment dosage and duration of adjuvant S-1 plus oxaliplatin in patients with stage III colon cancer (SOAP trial)
|
Suwa, Y.
|
|
|
32 |
S3 |
p. S161-S162
|
artikel
|
| 120 |
P-190 Exploring possible predictors of survival in hepatocellular carcinoma
|
Eiriz, I.
|
|
|
32 |
S3 |
p. S164-S165
|
artikel
|
| 121 |
P-44 Expression and clinical significance of B cell translocation gene 2 in esophageal squamous cell carcinoma
|
Wang, W.
|
|
|
32 |
S3 |
p. S110-S111
|
artikel
|
| 122 |
P-224 Expression of major components of the exosome biogenesis pathway is deregulated in colorectal cancer and associated with clinical outcome: Preliminary results from an association study
|
Kottorou, A.
|
|
|
32 |
S3 |
p. S175-S176
|
artikel
|
| 123 |
P-65 Expression of TIMP-1 level as a diagnostic and prognostic factor in colon cancer patients: A systematic review
|
Tandiono, J.
|
|
|
32 |
S3 |
p. S118-S119
|
artikel
|
| 124 |
P-131 External validation of prognostic ALAN score in patients with inoperable bile duct cancer treated with second-line chemotherapy
|
Giampieri, R.
|
|
|
32 |
S3 |
p. S143
|
artikel
|
| 125 |
P-282 Factors predicting response to neoadjuvant chemotherapy in gastric cancer
|
Kumar CG, P.
|
|
|
32 |
S3 |
p. S193
|
artikel
|
| 126 |
P-256 Fibroblast-induced paradoxical PI3K pathway activation in colorectal cancer: Role of PTEN and potential implications for PI3K/mTOR inhibition
|
Bazzichetto, C.
|
|
|
32 |
S3 |
p. S185
|
artikel
|
| 127 |
P-113 FIGHT-302: Phase 3 study of first-line pemigatinib vs gemcitabine + cisplatin for cholangiocarcinoma with FGFR2 fusions or rearrangement
|
Bekaii-Saab, T.
|
|
|
32 |
S3 |
p. S137
|
artikel
|
| 128 |
P-193 Final results of hepatectomy followed by adjuvant chemotherapy with 3-month capecitabine plus oxaliplatin for colorectal cancer liver metastases: A multicenter phase 2 study
|
Hashida, H.
|
|
|
32 |
S3 |
p. S165-S166
|
artikel
|
| 129 |
P-70 First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors
|
Goyal, L.
|
|
|
32 |
S3 |
p. S120
|
artikel
|
| 130 |
P-2 First-line atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma: A cost-effectiveness analysis
|
Chan, S.
|
|
|
32 |
S3 |
p. S97
|
artikel
|
| 131 |
P-207 FLOT in clinical practice: Retrospective analysis of an oncological center
|
Fontes, R.
|
|
|
32 |
S3 |
p. S170
|
artikel
|
| 132 |
P-47 5-fluorouracil bolus use in infusional regimens among oncologists: A survey by Brazilian Group of Gastrointestinal Tumors
|
Peixoto, R.
|
|
|
32 |
S3 |
p. S112
|
artikel
|
| 133 |
P-196 Frequency, biological behaviour and survival nomograms discrimination in non-KIT mutated gastrointestinal stromal tumors
|
Alpoim, T.
|
|
|
32 |
S3 |
p. S166-S167
|
artikel
|
| 134 |
P-11 GAME score in patients with liver metastases from colorectal cancer
|
Ben Kridis, W.
|
|
|
32 |
S3 |
p. S100
|
artikel
|
| 135 |
P-223 Gasdermin B predicts good prognosis and more macrophage infiltration
|
Xu, F.
|
|
|
32 |
S3 |
p. S175
|
artikel
|
| 136 |
P-195 Gastric adenocarcinoma classification: Association with clinicopathological features and overall survival in Moroccan patients
|
Nshizirungu, J.
|
|
|
32 |
S3 |
p. S166
|
artikel
|
| 137 |
P-289 Gastric and esophageal signet ring cell adenocarcinoma: A retrospective analysis of outcomes at Mayo Clinic
|
Kusne, Y.
|
|
|
32 |
S3 |
p. S195
|
artikel
|
| 138 |
P-3 Gastric cancer: 10-year survival
|
Kshivets, O.
|
|
|
32 |
S3 |
p. S97
|
artikel
|
| 139 |
P-122 Gastrointestinal side effects of morphine in cancer pain: A comparison between the smoking and non-smoking patients
|
Hijri, F.
|
|
|
32 |
S3 |
p. S140
|
artikel
|
| 140 |
P-216 Gender-specific genomic alterations among Hispanic patients with metastatic colorectal cancer
|
Philipovskiy, A.
|
|
|
32 |
S3 |
p. S172-S173
|
artikel
|
| 141 |
P-84 Genotype-fenotype correlation in patients with Lynch syndrome and colorectal cancer
|
Garcia-Cuesta, J.
|
|
|
32 |
S3 |
p. S126
|
artikel
|
| 142 |
P-1 Health-related quality of life of rectal cancer survivors treated with curative intent
|
Ferreira, A.
|
|
|
32 |
S3 |
p. S97
|
artikel
|
| 143 |
P-213 Helicobacter pylori babA gene evolution and adaptation in Colombian populations
|
Guzman, K.
|
|
|
32 |
S3 |
p. S171-S172
|
artikel
|
| 144 |
P-264 Helicobacter pylori SNPs associated with tetracycline, clarithromycin and amoxicillin resistance in Colombia
|
Guzman, K.
|
|
|
32 |
S3 |
p. S187-S188
|
artikel
|
| 145 |
P-159 HERIZON: Phase 2 part of the IMU-131 HER2/neu vaccine plus chemotherapy study randomized in patients with HER2/NEU overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction
|
Maglakelidze, M.
|
|
|
32 |
S3 |
p. S154
|
artikel
|
| 146 |
P-35 HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer: Analysis of first-line treatment
|
Ito, K.
|
|
|
32 |
S3 |
p. S108
|
artikel
|
| 147 |
P-81 HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer: Analysis of second-line treatment
|
Kaneko, S.
|
|
|
32 |
S3 |
p. S125
|
artikel
|
| 148 |
P-79 HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer: Analysis of second-line treatment after anti-EGFR antibody
|
Yoshikawa, A.
|
|
|
32 |
S3 |
p. S124
|
artikel
|
| 149 |
P-54 Higher muscle mass is associated with better response to concurrent neoadjuvant chemoradiotherapy in rectal cancer patients
|
Zhelev, K.
|
|
|
32 |
S3 |
p. S114-S115
|
artikel
|
| 150 |
P-16 How does reinduction of first-line chemotherapy in patients with metastatic colorectal cancer impact outcomes? Experience from the University Hospital for Tumors, Zagreb, Croatia
|
Pavlovic, M.
|
|
|
32 |
S3 |
p. S101
|
artikel
|
| 151 |
P-7 How much can GIT cancer patients afford for effective and safe treatment?
|
Aboelhassan, R.
|
|
|
32 |
S3 |
p. S98-S99
|
artikel
|
| 152 |
P-75 Impact of an educational activity on the knowledge of oncologists regarding the latest clinical trial data on HER2-directed therapies for gastric and colorectal cancer
|
Dorkhom, N.
|
|
|
32 |
S3 |
p. S122-S123
|
artikel
|
| 153 |
P-119 Impact of circulating tumor DNA on clinical decisions in the adjuvant setting in patients with colorectal cancer
|
Wookey, V.
|
|
|
32 |
S3 |
p. S139
|
artikel
|
| 154 |
P-270 Impact of intestinal stoma on quality of life in Tunisian patients with colorectal cancer
|
Melliti, R.
|
|
|
32 |
S3 |
p. S189-S190
|
artikel
|
| 155 |
P-294 Impact of surgical margin status on the survival outcome after surgical resection of gastric cancer: A systematic review and meta-analysis
|
Jiang, Z.
|
|
|
32 |
S3 |
p. S197
|
artikel
|
| 156 |
P-82 Impact of type 2 diabetes mellitus in overall survival and clinical features of Latin patients with colorectal cancer: A 15-year follow-up
|
Calderillo-Ruiz, G.
|
|
|
32 |
S3 |
p. S125-S126
|
artikel
|
| 157 |
P-293 Implementation of Medic Assistant: Solutions in a digital cloud supporting medical staff in their daily work with oncological patients during the SARS-COV2 pandemic
|
Kędzierska, M.
|
|
|
32 |
S3 |
p. S196-S197
|
artikel
|
| 158 |
P-288 Individual drug-screening and heterogeneity analyses of patient-derived tumoroids: A roadmap to improving therapy in pancreatic cancer
|
Nitschke, C.
|
|
|
32 |
S3 |
p. S195
|
artikel
|
| 159 |
P-128 Influence of anti-diabetic medications on the outcomes of patients with pancreatic ductal adenocarcinoma and type 2 diabetes mellitus
|
Pretta, A.
|
|
|
32 |
S3 |
p. S142
|
artikel
|
| 160 |
P-150 Insights into the gastric and oesophageal cancer patient experience: Results of a pan-European patient survey
|
Maravic, Z.
|
|
|
32 |
S3 |
p. S150
|
artikel
|
| 161 |
P-46 Integrated transcriptomics and the exploration of cancer-promoting genes CDKN3 in esophageal squamous cell cancer
|
Pan, Y.
|
|
|
32 |
S3 |
p. S111
|
artikel
|
| 162 |
P-149 Integrative analysis of the genomic and transcriptomic landscape identifies novel key genes as a therapeutic target in bile duct cancer
|
Salati, M.
|
|
|
32 |
S3 |
p. S150
|
artikel
|
| 163 |
P-69 Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience
|
Rizzo, A.
|
|
|
32 |
S3 |
p. S120
|
artikel
|
| 164 |
P-267 Interleukin-8 levels as a predictor of colorectal cancer patient prognosis
|
Conciatori, F.
|
|
|
32 |
S3 |
p. S188-S189
|
artikel
|
| 165 |
P-247 In vivo feasibility study of a robotic arm-assisted endoscopic submucosal dissection for early gastric cancer
|
Jeen, Y.
|
|
|
32 |
S3 |
p. S183
|
artikel
|
| 166 |
P-110 Is dexamethasone necessary as a prophylactic antiemetic prior to gemcitabine plus nab-paclitaxel therapy?
|
Murata, S.
|
|
|
32 |
S3 |
p. S136
|
artikel
|
| 167 |
P-230 Is stereotactic microwave ablation of resectable colorectal liver metastasis an alternative for liver resection in the Covid-19 pandemic?
|
Chapelle, T.
|
|
|
32 |
S3 |
p. S177-S178
|
artikel
|
| 168 |
P-30 Is vitamin D status known in patients with advanced pancreatic adenocarcinoma?
|
Uña Cidón, E.
|
|
|
32 |
S3 |
p. S106
|
artikel
|
| 169 |
P-71 KRYSTAL-10: A randomized phase 3 study of adagrasib (MRTX849) in combination with cetuximab vs chemotherapy in patients with previously treated advanced colorectal cancer with KRASG12C mutation
|
Tabernero, J.
|
|
|
32 |
S3 |
p. S121
|
artikel
|
| 170 |
P-183 Laparoscopic colorectal resection for elderly patients aged 80 years or older: A propensity score analysis
|
Inada, R.
|
|
|
32 |
S3 |
p. S162
|
artikel
|
| 171 |
P-40 Lenvatinib versus sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study
|
Rimini, M.
|
|
|
32 |
S3 |
p. S109
|
artikel
|
| 172 |
P-220 Linc01088 promotes the progression and tumor immune escape in colorectal cancer by sponging multiple microRNAs
|
Wang, S.
|
|
|
32 |
S3 |
p. S174
|
artikel
|
| 173 |
P-41 Lipopolysaccharides promote metastasis via acceleration of glycolysis by the nuclear factor-κB/Snail/Hexokinase3 signaling axis in colorectal cancer
|
Xu, F.
|
|
|
32 |
S3 |
p. S109-S110
|
artikel
|
| 174 |
P-12 Long intergenic non-protein coding RNA 1094 regulates the progression of gastric cancer
|
Ge, O.
|
|
|
32 |
S3 |
p. S100
|
artikel
|
| 175 |
P-249 Long-term oncologic safety of self-expandable metal stent as a bridge to surgery for obstructing colon cancer
|
Shim, J.
|
|
|
32 |
S3 |
p. S183
|
artikel
|
| 176 |
P-281 Low proliferation indexes in colorectal cancer in Tunisian patients: Association with rectal localization, mucinous histological type and stage
|
Wider, D.
|
|
|
32 |
S3 |
p. S193
|
artikel
|
| 177 |
P-127 Lymphocyte to monocyte ratio as a prognostic factor in stage IV pancreatic ductal adenocarcinoma naive patients before gemcitabine-nab-paclitaxel chemotherapy
|
Pretta, A.
|
|
|
32 |
S3 |
p. S142
|
artikel
|
| 178 |
P-138 Margetuximab combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) +/- chemotherapy in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction or gastric cancer
|
Catenacci, D.
|
|
|
32 |
S3 |
p. S146
|
artikel
|
| 179 |
P-63 MATTERHORN: A phase 3 study of efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer
|
Janjigian, Y.
|
|
|
32 |
S3 |
p. S118
|
artikel
|
| 180 |
P-241 Metastatic lymph node ratio as an addition to the nodal evaluation of TNM staging: A new sight for prevention of stage migrations
|
Tanal, M.
|
|
|
32 |
S3 |
p. S181
|
artikel
|
| 181 |
P-132 Molecular profiling of KIT and PDGFRA in Chilean GIST patients: A Latin-American perspective
|
Muñoz-Medel, M.
|
|
|
32 |
S3 |
p. S143-S144
|
artikel
|
| 182 |
P-164 MONEO: A phase II study of avelumab plus FLOT in the peri-operative treatment for patients with resectable gastric or gastroesophageal junction cancer
|
Alsina, M.
|
|
|
32 |
S3 |
p. S155-S156
|
artikel
|
| 183 |
P-174 MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in progress
|
Strickler, J.
|
|
|
32 |
S3 |
p. S159
|
artikel
|
| 184 |
P-273 Mucinous colorectal cancer in Tunisian patients: A controversial clinicopathological type
|
Guettiti Tounsi, H.
|
|
|
32 |
S3 |
p. S190-S191
|
artikel
|
| 185 |
P-251 Multidisciplinary challenge for the oncologist and surgeon: Gastrointestinal stromal tumors. Follow-up of a tertiary surgical department
|
Baran, E.
|
|
|
32 |
S3 |
p. S184
|
artikel
|
| 186 |
P-290 Mutant allele specific imbalance in RAS as prognostic marker in colorectal cancer
|
Kirshenboim, Y.
|
|
|
32 |
S3 |
p. S195-S196
|
artikel
|
| 187 |
P-141 Neoadjuvant chemotherapy with docetaxel, nedaplatin, and 5-FU for resectable esophageal cancer: A single center retrospective study
|
Shindo, S.
|
|
|
32 |
S3 |
p. S147
|
artikel
|
| 188 |
P-265 Neoadjuvant radiotherapy for locally advanced rectal cancer during the first wave of COVID19 pandemic: Guy’s cancer cohort experience
|
Sachdeva, A.
|
|
|
32 |
S3 |
p. S188
|
artikel
|
| 189 |
P-124 Nivolumab plus ipilimumab as neoadjuvant therapy for potentially resectable hepatocellular carcinoma
|
Su, Y.
|
|
|
32 |
S3 |
p. S141
|
artikel
|
| 190 |
P-8 Nutritional status among colorectal cancer patients in Tunisia
|
Zribi, A.
|
|
|
32 |
S3 |
p. S99
|
artikel
|
| 191 |
P-49 Oesophageal neuroendocrine carcinoma: Retrospective evaluation of outcomes from a UK tertiary centre
|
Tilby, M.
|
|
|
32 |
S3 |
p. S112
|
artikel
|
| 192 |
P-266 Oncological outcomes of self-expanding metal stent as a bridge to surgery for obstructive left-sided colon cancer
|
Gomez Fernandez, L.
|
|
|
32 |
S3 |
p. S188
|
artikel
|
| 193 |
P-166 Operative versus nonoperative treatment for stage 0 rectal cancer following chemoradiation therapy
|
Aires, F.
|
|
|
32 |
S3 |
p. S156
|
artikel
|
| 194 |
P-215 Outcomes following surgery for resectable pancreatic neuroendocrine tumors: A Brazilian single institutional experience
|
Arra, D.
|
|
|
32 |
S3 |
p. S172
|
artikel
|
| 195 |
P-62 Overall survival of patients with pancreatic cancer
|
Flores, C.
|
|
|
32 |
S3 |
p. S117-S118
|
artikel
|
| 196 |
P-52 Overall survival with cetuximab every 2 weeks vs standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumor location
|
Kasper, S.
|
|
|
32 |
S3 |
p. S114
|
artikel
|
| 197 |
P-29 Pancreatic cancer during the COVID-19 pandemic: A high-volume Polish centre experience
|
Durlik, M.
|
|
|
32 |
S3 |
p. S106
|
artikel
|
| 198 |
P-36 Pancreatic cancer in times of the pandemic
|
Una Cidon, E.
|
|
|
32 |
S3 |
p. S108
|
artikel
|
| 199 |
P-208 Pancreatic neuroendocrine neoplasia: Experience of a comprehensive cancer center
|
Coelho, S.
|
|
|
32 |
S3 |
p. S170
|
artikel
|
| 200 |
P-234 Participation of screening and barriers in Chinese patients with advanced colorectal cancer before diagnosis: A national multi-center cross-sectional study
|
Liu, Y.
|
|
|
32 |
S3 |
p. S179
|
artikel
|
| 201 |
P-137 Patient baseline characteristics in the PROMETCO study: A real-world, prospective longitudinal cohort on the continuum of care of metastatic colorectal cancer
|
Koopman, M.
|
|
|
32 |
S3 |
p. S145-S146
|
artikel
|
| 202 |
P-233 Patient information and management by eHealth intervention during colon cancer
|
Jorge, T.
|
|
|
32 |
S3 |
p. S178-S179
|
artikel
|
| 203 |
P-135 Pembrolizumab/quavonlimab coformulation in combination with lenvatinib in advanced hepatocellular carcinoma: Phase 2 trial in progress
|
Li, D.
|
|
|
32 |
S3 |
p. S144-S145
|
artikel
|
| 204 |
P-148 Perfect concordance between blood-based and normal tissue-based dihydropyrimidine dehydrogenase polymorphisms suggests that pharmacogenetic screening could be contextual to tumour molecular profiling
|
Morelli, C.
|
|
|
32 |
S3 |
p. S149
|
artikel
|
| 205 |
P-111 PERSPECTIVE: Tepotinib plus cetuximab in patients with RAS/BRAF wild-type left-sided metastatic colorectal cancer and acquired resistance to anti-EGFR antibody therapy due to MET amplification
|
Tabernero, J.
|
|
|
32 |
S3 |
p. S136-S137
|
artikel
|
| 206 |
P-18 Phase Ib study of niraparib plus tebotelimab in patients with advanced or metastatic gastric cancer after prior treatment failure
|
Xu, R.
|
|
|
32 |
S3 |
p. S102
|
artikel
|
| 207 |
P-228 Phase II multicentric randomized controlled trial to compare first-line treatment with FOLFOX6m + mAB alone or in combination with liver chemoembolization (Lifepearls-Irinotecan) in poor prognosis colorectal cancer with liver-limited disease
|
Paez, D.
|
|
|
32 |
S3 |
p. S177
|
artikel
|
| 208 |
P-261 Phase I study of multiple kinase inhibitor, TT-00420, in advanced, refractory cholangiocarcinoma
|
Piha-Paul, S.
|
|
|
32 |
S3 |
p. S186-S187
|
artikel
|
| 209 |
P-260 Plasma exRNA-based identification of novel biomarkers in early gastric cancer
|
Xing, S.
|
|
|
32 |
S3 |
p. S186
|
artikel
|
| 210 |
P-105 POLO: Patient-centred outcomes with maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer
|
Kindler, H.
|
|
|
32 |
S3 |
p. S134
|
artikel
|
| 211 |
P-143 Polyphyllin Ⅱ and resiquimod-loaded injectable hydrogels promote the polarization of tumor-associated macrophages and enhance gastric cancer immunotherapy
|
Yang, Y.
|
|
|
32 |
S3 |
p. S148
|
artikel
|
| 212 |
P-78 Post hoc analysis in patients with unresectable hepatocellular carcinoma who progressed to Child-Pugh B liver function in the phase 3 REFLECT study of lenvatinib vs sorafenib
|
Huynh, J.
|
|
|
32 |
S3 |
p. S123-S124
|
artikel
|
| 213 |
P-120 Pre-assessment tool predicting complication following oesophagogastric resection: Sarcopenia or incremental shuttle walk test
|
Siddaiah-Subramanya, M.
|
|
|
32 |
S3 |
p. S139
|
artikel
|
| 214 |
P-287 Preclinical evaluation of alpelisib (PI3K inhibitor) and its synergistic effect in combination with ribociclib (CDK 4/6 inhibitor) in colorectal cancer
|
Aslam, R.
|
|
|
32 |
S3 |
p. S194-S195
|
artikel
|
| 215 |
P-10 Prevalence and risk factors of chronic neuropathy in 225 colorectal cancer patients treated with oxaliplatin-based regimens in Tunisia
|
Zribi, A.
|
|
|
32 |
S3 |
p. S99-S100
|
artikel
|
| 216 |
P-198 Prevalence of deleterious DPYD variants in patients with gastrointestinal malignancies: Real-world data from a single institution in Italy
|
Cardone, C.
|
|
|
32 |
S3 |
p. S167
|
artikel
|
| 217 |
P-202 Primary tumour location and efficacy of first-line anti-EGFR agents in the treatment of RAS wild-type metastatic colorectal cancer
|
Marinho, J.
|
|
|
32 |
S3 |
p. S168-S169
|
artikel
|
| 218 |
P-4 Prognostic and therapeutic values of tumor-infiltrating lymphocytes in localized colon cancer
|
Ben Nasr, S.
|
|
|
32 |
S3 |
p. S98
|
artikel
|
| 219 |
P-53 Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis
|
Broadbent, R.
|
|
|
32 |
S3 |
p. S114
|
artikel
|
| 220 |
P-50 Prognostic factors in patients receiving trifluridine/tipiracil for refractory metastatic colorectal cancer in the real-life setting: The ROS study
|
García-Alfonso, P.
|
|
|
32 |
S3 |
p. S113
|
artikel
|
| 221 |
P-283 Prognostic factors in the evaluation of stage II/III squamous cell carcinoma of the anus treated with chemoradiation
|
Gramaça, J.
|
|
|
32 |
S3 |
p. S193
|
artikel
|
| 222 |
P-191 Prognostic factors of colorectal cancer liver metastasectomy
|
Costa, I.
|
|
|
32 |
S3 |
p. S165
|
artikel
|
| 223 |
P-67 Prognostic implication of HER2 overexpression in surgically treated patients with gastric cancer
|
Enkhbat, E.
|
|
|
32 |
S3 |
p. S119
|
artikel
|
| 224 |
P-232 Prognostic inflammatory and microRNA biomarkers in stage IV colorectal cancer patients
|
Nassar, F.
|
|
|
32 |
S3 |
p. S178
|
artikel
|
| 225 |
P-9 Prognostic role of preoperative inflammation parameters in predicting postoperative complications of colorectal cancer surgery
|
Melliti, R.
|
|
|
32 |
S3 |
p. S99
|
artikel
|
| 226 |
P-188 Propensity score analysis of outcomes following laparoscopic or open radical resection for gallbladder carcinoma in T2 and T3 stages
|
Dou, C.
|
|
|
32 |
S3 |
p. S164
|
artikel
|
| 227 |
P-172 PTHrP and SPARC expressions in human colorectal cancer: An in silico analysis
|
Carriere, P.
|
|
|
32 |
S3 |
p. S158
|
artikel
|
| 228 |
P-219 Real-life experience with chemotherapy plus biologics in first-line treatment of right-sided, RAS wild-type, metastatic colon cancer: A multicenter Onco-Colon Turkey study
|
Ç. Arslan,
|
|
|
32 |
S3 |
p. S174
|
artikel
|
| 229 |
P-87 Real-world data of nivolumab in advanced hepatocellular carcinoma: A multi-centric and retrospective study
|
Sardinha, M.
|
|
|
32 |
S3 |
p. S127
|
artikel
|
| 230 |
P-34 Real-world efficacy and safety of immune checkpoint inhibitors in microsatellite unstable or mismatch repair deficient gastrointestinal tumors
|
Martínez Lago, N.
|
|
|
32 |
S3 |
p. S107
|
artikel
|
| 231 |
P-31 Real-world efficacy and safety of trifluridine/tipiracil plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies
|
Martínez Lago, N.
|
|
|
32 |
S3 |
p. S106-S107
|
artikel
|
| 232 |
P-21 Real-world outcomes in patients with advanced or metastatic gastric adenocarcinoma in the United States
|
Beachler, D.
|
|
|
32 |
S3 |
p. S103
|
artikel
|
| 233 |
P-163 Real-world outcomes of cisplatin, capecitabine and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as first-line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma
|
Waldron, N.
|
|
|
32 |
S3 |
p. S155
|
artikel
|
| 234 |
P-130 Real-world outcomes of patients with colorectal liver metastases treated with transarterial radioembolization: Results from CIRT, a large European, prospective multi-centre, observational study
|
Schaefer, N.
|
|
|
32 |
S3 |
p. S143
|
artikel
|
| 235 |
P-180 Rectal cancer in the elderly: Characteristics, management and outcomes from a single centre retrospective cohort review
|
Hamed, R.
|
|
|
32 |
S3 |
p. S161
|
artikel
|
| 236 |
P-42 Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies as treatment option in vulnerable older patients with metastatic colorectal cancer: A retrospective cohort study
|
Rosati, G.
|
|
|
32 |
S3 |
p. S110
|
artikel
|
| 237 |
P-178 Rego-Nivo II-III: Proof-of-concept phase II trial for the treatment of HCC refractory to chemotherapy after the 2nd line
|
Ben Merabet, Y.
|
|
|
32 |
S3 |
p. S160-S161
|
artikel
|
| 238 |
P-26 Regorafenib versus cabozantinib as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: Matching-adjusted indirect comparison analysis
|
Casadei Gardini, A.
|
|
|
32 |
S3 |
p. S105
|
artikel
|
| 239 |
P-85 Relationship between microsatellite instability and neoadjuvant chemotherapy response in gastric or gastroesophageal junction cancer: A meta-analysis
|
Ergun, Y.
|
|
|
32 |
S3 |
p. S126-S127
|
artikel
|
| 240 |
P-203 Relationship of myelotoxicity and of gastrointestinal toxicity with the treatment outcome in trials of second-line chemotherapy of patients with metastatic colorectal cancer
|
Venturino, A.
|
|
|
32 |
S3 |
p. S169
|
artikel
|
| 241 |
P-61 Relatlimab + nivolumab in patients with advanced hepatocellular carcinoma who are naive to immuno-oncology therapy but progressed on tyrosine kinase inhibitors, a phase 2, randomized, open-label study: RELATIVITY-073
|
Sangro, B.
|
|
|
32 |
S3 |
p. S117
|
artikel
|
| 242 |
P-221 Repurposing disulfiram as treatment for metastatic colorectal cancer: An investigator-initiated clinical phase II trial
|
Tarpgaard, L.
|
|
|
32 |
S3 |
p. S174-S175
|
artikel
|
| 243 |
P-252 Residual fibrosis after treatment with anti-epidermal growth factor receptor or bevacizumab in colorectal liver metastases and its correlation with survival: A retrospective pooled analysis
|
Hernández-Yagüe, X.
|
|
|
32 |
S3 |
p. S184
|
artikel
|
| 244 |
P-68 Response to neoadjuvant chemotherapy in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma with FLOT-regimen in our setting
|
Garcia Grove, C.
|
|
|
32 |
S3 |
p. S119
|
artikel
|
| 245 |
P-33 Results of initial DPYD screening for cancer patients receiving fluoropyrimidines
|
Bolaños Naranjo, M.
|
|
|
32 |
S3 |
p. S107
|
artikel
|
| 246 |
P-201 Retrospective evaluation of patients with colorectal cancer with metastasis in the central nervous system: Clinical and epidemiological prognostic factors
|
Sá, D.
|
|
|
32 |
S3 |
p. S168
|
artikel
|
| 247 |
P-77 Risk factors and clinical outcomes of post-gastrectomy sarcopenia newly developed after curative resection for gastric cancer
|
Kim, B.
|
|
|
32 |
S3 |
p. S123
|
artikel
|
| 248 |
P-211 Risk of diabetes in subjects with positive fecal immunochemical test: A nationwide population-based study
|
Lee, H.
|
|
|
32 |
S3 |
p. S171
|
artikel
|
| 249 |
P-104 Risk of nausea and vomiting in a real-world data cohort of chemotherapy-treated patients with metastatic gastric or gastroesophageal junction adenocarcinoma by medical history of gastrectomy
|
de Vogel, S.
|
|
|
32 |
S3 |
p. S133-S134
|
artikel
|
| 250 |
P-254 Role of neutrophil-lymphocyte ratio in the prognosis of stomach carcinoma undergoing curative resection
|
Ambre, S.
|
|
|
32 |
S3 |
p. S185
|
artikel
|
| 251 |
P-244 Role of preoperative contrast-enhanced computed tomography in staging of gastric cancer in patients undergoing upfront surgery with curative intent
|
Colney, L.
|
|
|
32 |
S3 |
p. S182
|
artikel
|
| 252 |
P-22 Role of timing to laparoscopic or robotic surgery after neoadjuvant chemoradiotherapy for rectal cancer: The TiMiSNAR trial
|
Monsellato, I.
|
|
|
32 |
S3 |
p. S103
|
artikel
|
| 253 |
P-153 Safety and effectiveness of sorafenib in elderly patients diagnosed with advanced hepatocellular carcinoma in a monographic oncologic center
|
Vidales Sepulveda, Z.
|
|
|
32 |
S3 |
p. S151
|
artikel
|
| 254 |
P-142 Safety and efficacy of apatinib for non-surgical advanced esophageal cancer: A real-world study
|
Sun, C.
|
|
|
32 |
S3 |
p. S147
|
artikel
|
| 255 |
P-91 Safety and efficacy of perioperative FLOT in elderly patients: Real-world data
|
Baleiras, M.
|
|
|
32 |
S3 |
p. S128-S129
|
artikel
|
| 256 |
P-189 Safety and feasibility of liposomal irinotecan for unresectable pancreatic adenocarcinoma: Real-world experience in a Japanese cohort
|
Sakai, A.
|
|
|
32 |
S3 |
p. S164
|
artikel
|
| 257 |
P-152 Sarcopenia in advanced colorectal cancer patients treated with trifluridine/tipiracil
|
Malik, M.
|
|
|
32 |
S3 |
p. S151
|
artikel
|
| 258 |
P-32 SARS-CoV-2 pandemic and delayed presentation of gastrointestinal cancer patients: A retrospective evaluation and the impact on clinical outcome
|
Ida Bagus, B.
|
|
|
32 |
S3 |
p. S107
|
artikel
|
| 259 |
P-268 Seaweed laminaria japonica peptides possess strong anti-liver cancer effects
|
Chen, H.
|
|
|
32 |
S3 |
p. S189
|
artikel
|
| 260 |
P-276 Sex and regorafenib toxicity in refractory colorectal cancer: A safety analysis of the RegARd-C trial
|
Vandeputte, C.
|
|
|
32 |
S3 |
p. S191-S192
|
artikel
|
| 261 |
P-37 SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations: Biliary tract cancer cohort (trial in progress)
|
Bekaii-Saab, T.
|
|
|
32 |
S3 |
p. S108-S109
|
artikel
|
| 262 |
P-214 Should patients with active gastrointestinal tumors receive thromboprophylaxis to avoid the negative clinical consequences of CAT? Sub-analysis of ACT4CAT study
|
Tsoukalas, N.
|
|
|
32 |
S3 |
p. S172
|
artikel
|
| 263 |
P-272 Significance of adding oxaliplatin to postoperative adjuvant chemotherapy in elderly patients with colorectal cancer
|
Nagata, Y.
|
|
|
32 |
S3 |
p. S190
|
artikel
|
| 264 |
P-134 Social determinants of health are risk factors for early onset colorectal cancer in Appalachia
|
Oelsner, W.
|
|
|
32 |
S3 |
p. S144
|
artikel
|
| 265 |
P-88 Sorafenib for hepatocellular carcinoma in real life
|
Una Cidon, E.
|
|
|
32 |
S3 |
p. S127
|
artikel
|
| 266 |
P-80 Sorafenib in extended patient populations in real-world clinical practice: Baseline characteristics from OPTIMIS and GIDEON
|
Peck-Radosavljevic, M.
|
|
|
32 |
S3 |
p. S124-S125
|
artikel
|
| 267 |
P-6 Spatio-temporal distribution pattern of pancreatic cancer mortality rate in Peru between 2003-2017
|
Flores, C.
|
|
|
32 |
S3 |
p. S98
|
artikel
|
| 268 |
P-262 Staining plasma with lipophilic dye followed by size-exclusion chromatography, immune-capturing and on-bead flow cytometry is a highly sensitive approach to quantifying colorectal cancer derived extracellular nanovesicles
|
Nikiforova, N.
|
|
|
32 |
S3 |
p. S187
|
artikel
|
| 269 |
P-218 STAT3 signaling inhibition in regulatory T cells improves immune response to RT in PDAC
|
Piper, M.
|
|
|
32 |
S3 |
p. S173
|
artikel
|
| 270 |
P-194 Study of efficacy and safety of combination of octreotide acetate LAR with lenvatinib as second-line therapy in patients with advanced G1-G2 NETs of non-pancreatic origin
|
Goel, V.
|
|
|
32 |
S3 |
p. S166
|
artikel
|
| 271 |
P-48 Study of paclitaxel and ramucirumab as second-line therapy after failure of FOLFOX-6 regimen in metastatic stomach carcinoma patients
|
Goel, V.
|
|
|
32 |
S3 |
p. S112
|
artikel
|
| 272 |
P-123 Survival analysis based on the grade of neutropenia in patients with metastatic colorectal cancer treated with trifluridine-tipiracil
|
Aviñó Tarazona, V.
|
|
|
32 |
S3 |
p. S140
|
artikel
|
| 273 |
P-206 Survival comparison of first-line therapies in locally advanced or metastatic pancreatic cancer: A Portuguese oncology unit experience
|
Gameiro-dos-Santos, R.
|
|
|
32 |
S3 |
p. S169
|
artikel
|
| 274 |
P-204 Survival improvement from the addition of biologics is not affected by performance status in patients with metastatic colorectal cancer: A meta-analysis
|
Colloca, G.
|
|
|
32 |
S3 |
p. S169
|
artikel
|
| 275 |
P-101 Survival of early-onset gastric signet ring cell carcinoma in the Korean population between 2010 and 2015: Analysis of the Korea Central Cancer Registry database
|
Kim, H.
|
|
|
32 |
S3 |
p. S132
|
artikel
|
| 276 |
P-117 Survival outcomes following systemic chemotherapy in stage IVA/B high-grade mucinous appendiceal cancer after unsuccessful cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
|
Baron, E.
|
|
|
32 |
S3 |
p. S138
|
artikel
|
| 277 |
P-118 Survival outcomes of adjuvant chemotherapy in stage IVA/B high-grade appendiceal cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
|
Baron, E.
|
|
|
32 |
S3 |
p. S139
|
artikel
|
| 278 |
P-229 Systematic review and pooled analysis of locoregional therapies in patients with intrahepatic cholangiocarcinoma
|
Edeline, J.
|
|
|
32 |
S3 |
p. S177
|
artikel
|
| 279 |
P-231 Systemic inflammatory biomarkers and their association with survival in gastroesophageal cancer patients: A retrospective single-center analysis
|
Puhr, H.
|
|
|
32 |
S3 |
p. S178
|
artikel
|
| 280 |
P-271 The anti-tumor effect of Curcuma phaeocaulis cyclopeptide in human hepatoma HepG2 cells
|
Chen, H.
|
|
|
32 |
S3 |
p. S190
|
artikel
|
| 281 |
P-93 The characteristics and prognosis of extragastrointestinal stromal tumors: A single center retrospective analysis of 31 patients
|
Mu, M.
|
|
|
32 |
S3 |
p. S129
|
artikel
|
| 282 |
P-255 The clinical significance of the gut microbiota in RAS wild-type metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies in combination with chemotherapy – preliminary results
|
Lewandowski, T.
|
|
|
32 |
S3 |
p. S185
|
artikel
|
| 283 |
P-89 The correlation between adverse events and survival benefits of donafenib in the first-line treatment of advanced hepatocellular carcinoma
|
Bi, F.
|
|
|
32 |
S3 |
p. S128
|
artikel
|
| 284 |
P-240 The diagnosis and treatment of advanced colorectal cancer in China: A national multi-center cross-sectional study
|
Xu, H.
|
|
|
32 |
S3 |
p. S180-S181
|
artikel
|
| 285 |
P-161 The diagnostic methods for detection of Helicobacter pylori infection: A comparative approach to invasive methods
|
Castro-Valencia, F.
|
|
|
32 |
S3 |
p. S154-S155
|
artikel
|
| 286 |
P-263 The effects of co-administration of erlotinib and apatinib in the treatment oesophageal squamous cell carcinoma
|
Lin, Y.
|
|
|
32 |
S3 |
p. S187
|
artikel
|
| 287 |
P-27 The efficacy and safety of XELOX/SOX plus bevacizumab as neoadjuvant chemotherapy for locally advanced rectal cancer compared with XELOX/SOX: A retrospective study
|
Sakaguchi, N.
|
|
|
32 |
S3 |
p. S105
|
artikel
|
| 288 |
P-83 The efficacy of chemotherapy for gastric cancer with early recurrence during or after adjuvant S-1
|
Kumagai, K.
|
|
|
32 |
S3 |
p. S126
|
artikel
|
| 289 |
P-212 The genetic and epigenetic abnormalities of plasma cfDNA as liquid biopsy biomarkers for diagnosis and prognosis stratification of pancreatic ductal adenocarcinoma
|
Wang, Y.
|
|
|
32 |
S3 |
p. S171
|
artikel
|
| 290 |
P-74 The impact of first-line chemotherapy in elderly patients with advanced pancreatic cancer: A mono-institutional retrospective study
|
Maratta, M.
|
|
|
32 |
S3 |
p. S122
|
artikel
|
| 291 |
P-64 The impact of sarcopenia on overall survival among cholangiocarcinoma patients: A systematic review and meta-analysis
|
Marcella, E.
|
|
|
32 |
S3 |
p. S118
|
artikel
|
| 292 |
P-102 The importance of maintenance chemotherapy in the first and second lines of treatment of metastatic colorectal cancer
|
Gridnev, D.
|
|
|
32 |
S3 |
p. S132-S133
|
artikel
|
| 293 |
P-295 The importance of sphingosine kinase 1 isoform expression in the gut-liver axis
|
Chen, H.
|
|
|
32 |
S3 |
p. S197
|
artikel
|
| 294 |
P-86 The importance of sphingosine kinase 1 isoform expression in the gut-liver axis
|
Chen, H.
|
|
|
32 |
S3 |
p. S127
|
artikel
|
| 295 |
P-197 The influence of proton pump inhibitor utilization on the pathological response of rectal cancer: A multicenter study by the Sociedad Latino Americana de Oncologia Gastrointestinal (SLAGO)
|
Cesca, M.
|
|
|
32 |
S3 |
p. S167
|
artikel
|
| 296 |
P-217 The knowledge and awareness for colorectal cancer in advanced colorectal cancer patients in China: A national multicenter study
|
Xu, H.
|
|
|
32 |
S3 |
p. S173
|
artikel
|
| 297 |
P-92 The neuroendocrine tumor diagnostic process and the role of gastrointestinal specialists
|
Leyden, S.
|
|
|
32 |
S3 |
p. S129
|
artikel
|
| 298 |
P-14 The predictive value of alkaline phosphatase and lactate dehydrogenase for overall survival in patients with pancreatic cancer
|
Bengueddach, A.
|
|
|
32 |
S3 |
p. S100
|
artikel
|
| 299 |
P-291 The prognostic and predictive factors for patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy
|
Acun, M.
|
|
|
32 |
S3 |
p. S196
|
artikel
|
| 300 |
P-151 The prognostic value of TCF1+CD8+T cell in primary small cell carcinoma of the esophagus
|
Ma, L.
|
|
|
32 |
S3 |
p. S150-S151
|
artikel
|
| 301 |
P-73 The role of site of metastatic resection in metastatic colorectal cancer patients: A mono-institutional cohort study
|
Camarda, F.
|
|
|
32 |
S3 |
p. S122
|
artikel
|
| 302 |
P-39 The role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib
|
Rimini, M.
|
|
|
32 |
S3 |
p. S109
|
artikel
|
| 303 |
P-5 The use of complementary and alternative medicine among colorectal cancer patients in Tunisia
|
Zribi, A.
|
|
|
32 |
S3 |
p. S98
|
artikel
|
| 304 |
P-133 The watch-and-wait approach in stage IV rectal cancer patients: A good alternative for TME surgery?
|
Custers, P.
|
|
|
32 |
S3 |
p. S144
|
artikel
|
| 305 |
P-279 Thromboembolic complications in colorectal cancers
|
Mkedder, N.
|
|
|
32 |
S3 |
p. S192-S193
|
artikel
|
| 306 |
P-285 Treatment outcomes with sorafenib in advanced hepatocellular carcinoma: A single-center retrospective study
|
Prejac, J.
|
|
|
32 |
S3 |
p. S194
|
artikel
|
| 307 |
P-226 Trifluridin/tipiracil and regorafenib sequencing in Slovenian patients with metastatic colorectal cancer
|
Mesti, T.
|
|
|
32 |
S3 |
p. S176
|
artikel
|
| 308 |
P-292 Tumor downstaging as an associated factor with recurrence of disease in patients with operated rectal cancer after neoadjuvant chemoradiotherapy: Real-world data from Peru
|
Motta, R.
|
|
|
32 |
S3 |
p. S196
|
artikel
|
| 309 |
P-169 Tumor-infiltrating lymphocytes in colorectal cancer: A clinical outcome predictor
|
Vitorino, M.
|
|
|
32 |
S3 |
p. S157
|
artikel
|
| 310 |
P-184 Underlining mechanism for the efficacy of tumor treating fields (TTFields) concomitant with sorafenib for treatment of hepatocellular carcinoma
|
Davidi, S.
|
|
|
32 |
S3 |
p. S162-S163
|
artikel
|
| 311 |
P-94 Unicentric real-world data from esophageal cancer neoadjuvant treatment according to the CROSS trial protocol
|
Mendonça, J.
|
|
|
32 |
S3 |
p. S129-S130
|
artikel
|
| 312 |
P-162 Universally adopted vitamin D deficiency cutoff of 10 ng/mL is optimal for metastatic colorectal cancer prognostication and correlated with neutrophil/lymphocyte ratio
|
Rofei, M.
|
|
|
32 |
S3 |
p. S155
|
artikel
|
| 313 |
P-38 Unmet needs and concerns of Russian patients with CRC: Analysis of Russian internet postings
|
Khomitskaya, Y.
|
|
|
32 |
S3 |
p. S109
|
artikel
|
| 314 |
P-97 Updated results of HGCSG1603: A phase 2 trial of ramucirumab plus irinotecan combination therapy as second-line treatment for patients with advanced gastric cancer
|
Nakamura, M.
|
|
|
32 |
S3 |
p. S131
|
artikel
|
| 315 |
P-297 Upfront dihydropyrimidine dehydrogenase deficiency detection to secure 5-FU or capecitabine administration: Application to colorectal cancer patients
|
Mkedder, N.
|
|
|
32 |
S3 |
p. S198
|
artikel
|
| 316 |
P-57 US real-world ramucirumab and immune checkpoint inhibitor treatment sequences in advanced gastric, gastroesophageal junction, or esophageal cancer
|
Liepa, A.
|
|
|
32 |
S3 |
p. S116
|
artikel
|
| 317 |
P-186 Vimentin-positive circulating tumor cells as diagnostic and prognostic biomarkers in biliary tract cancer patients
|
Han, S.
|
|
|
32 |
S3 |
p. S163
|
artikel
|
| 318 |
P-187 Watch-and-wait strategy for DNA mismatch repair-deficient/microsatellite instability-high rectal cancer with a clinical complete response after neoadjuvant immunotherapy: An observational cohort study
|
Wang, Q.
|
|
|
32 |
S3 |
p. S163-S164
|
artikel
|
| 319 |
P-116 What have we learned about of trifluridine/tipiracil (TAS-102)? Real World Data at four GEODA hospitals (Spain)
|
Martínez Pérez, J.
|
|
|
32 |
S3 |
p. S138
|
artikel
|
| 320 |
P-160 Young Latin American population with colorectal cancer: Characteristics of bad prognosis
|
Calderillo-Ruiz, G.
|
|
|
32 |
S3 |
p. S154
|
artikel
|
| 321 |
SO-19 A multicenter phase Ⅱ trial of trifluridine/tipiracil in combination with cetuximab in RAS wild-type metastatic colorectal cancer patients refractory to prior anti-EGFR antibody therapy: The WJOG8916G trial
|
Masuishi, T.
|
|
|
32 |
S3 |
p. S210-S211
|
artikel
|
| 322 |
SO-9 Analysis of the immune-related endpoints of the mismatch repair–deficient non-endometrial solid cancers cohort from the GARNET study
|
André, T.
|
|
|
32 |
S3 |
p. S205-S206
|
artikel
|
| 323 |
SO-10 An open-label, multi-centre, phase Ib/II study of PI3Kβ selective inhibitor GSK2636771 administered in combination with paclitaxel in patients with advanced gastric cancer having alterations in PI3K/Akt pathway
|
Jung, M.
|
|
|
32 |
S3 |
p. S206
|
artikel
|
| 324 |
SO-31 ASPEN-01: A phase 1 study of ALX148, a CD47 blocker, in combination with trastuzumab, ramucirumab and paclitaxel in patients with second-line HER2-positive advanced gastric or gastroesophageal junction cancer
|
Chung, H.
|
|
|
32 |
S3 |
p. S215-S216
|
artikel
|
| 325 |
SO-24 Circulating tumor DNA variant allelic fraction as a surrogate for disease burden estimation in patients with RAS wild-type metastatic colorectal cancer: A secondary endpoint of the VALENTINO study
|
Manca, P.
|
|
|
32 |
S3 |
p. S212
|
artikel
|
| 326 |
SO-28 Effect of prior bevacizumab treatment in BRAF V600E-mutant metastatic colorectal cancer: Overall survival with encorafenib + cetuximab +/- binimetinib in BEACON CRC
|
Aderka, D.
|
|
|
32 |
S3 |
p. S214
|
artikel
|
| 327 |
SO-29 Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion-positive gastrointestinal cancer: An expanded dataset
|
Boni, V.
|
|
|
32 |
S3 |
p. S214-S215
|
artikel
|
| 328 |
SO-30 Efficacy and safety of neoadjuvant short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma: Averectal study
|
Shamseddine, A.
|
|
|
32 |
S3 |
p. S215
|
artikel
|
| 329 |
SO-25 Global rise in early-onset colorectal cancer: An association with antibiotic consumption?
|
Perrott, S.
|
|
|
32 |
S3 |
p. S213
|
artikel
|
| 330 |
SO-8 Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair deficient advanced solid tumors: Results from the KEYNOTE-158 study
|
Maio, M.
|
|
|
32 |
S3 |
p. S205
|
artikel
|
| 331 |
SO-21 Impact of timing of perioperative chemotherapy on survival outcomes among patients with colorectal liver metastases: A propensity score matching of the national cancer database
|
Baidoun, F.
|
|
|
32 |
S3 |
p. S211
|
artikel
|
| 332 |
SO-22 Importance order of risk factors for mortality in colon cancer stage II: A multivariate adaptive regression spline (MARS) analysis
|
Fabregas, J.
|
|
|
32 |
S3 |
p. S211-S212
|
artikel
|
| 333 |
SO-26 In-silico Lynch syndrome-related neoantigens prediction for a dendritic cell-based cancer prevention vaccine
|
Bayó, C.
|
|
|
32 |
S3 |
p. S213
|
artikel
|
| 334 |
SO-11 KISIMA-01 trial: Safety, tolerability and immunogenicity of ATP128 with or without ezabenlimab (BI 754091) in patients with stage IV colorectal cancer – preliminary results from a phase 1b study
|
Kopetz, S.
|
|
|
32 |
S3 |
p. S206-S207
|
artikel
|
| 335 |
SO-13 KRAS-G12C mutations in a Nordic cohort of 1441 metastatic colorectal cancer patients
|
Osterlund, E.
|
|
|
32 |
S3 |
p. S207-S208
|
artikel
|
| 336 |
SO-6 Microarchitectural changes in regional lymph nodes after chemotherapy in oesophageal cancer: Results from the UK MRC OE02 trial
|
Kloft, M.
|
|
|
32 |
S3 |
p. S204
|
artikel
|
| 337 |
SO-27 Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
|
André, T.
|
|
|
32 |
S3 |
p. S213-S214
|
artikel
|
| 338 |
SO-2 Pancreatic cancer in HIV versus non-HIV population: Analysis of demographics, outcomes and healthcare utilization from a national sample
|
Sherazi, S.
|
|
|
32 |
S3 |
p. S202
|
artikel
|
| 339 |
SO-4 Progression-free survival in patients with cholangiocarcinoma with FGFR2 fusions or rearrangements: A FIGHT-202 post-hoc analysis of prior systemic therapy response
|
Abou-Alfa, G.
|
|
|
32 |
S3 |
p. S203-S204
|
artikel
|
| 340 |
SO-20 Prospective validation of Ang-2 and Tie-2 plasma levels as predictors of benefit from regorafenib in metastatic colorectal cancer patients: REGOLAND study
|
Antoniotti, C.
|
|
|
32 |
S3 |
p. S211
|
artikel
|
| 341 |
SO-15 Quality of life and physical functioning in older patients with metastatic colorectal cancer receiving palliative chemotherapy: The randomized NORDIC9-study
|
Liposits, G.
|
|
|
32 |
S3 |
p. S208
|
artikel
|
| 342 |
SO-16 Quality of life in Finnish metastatic colorectal cancer patients actively treated with the aim of maximizing resection and/or local ablative therapy (RAXO-study NCT01531595)
|
Osterlund, P.
|
|
|
32 |
S3 |
p. S209
|
artikel
|
| 343 |
SO-18 Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: Final results according to duration of treatment from the phase IIIb, international, open-label, early-access PRECONNECT study
|
Taieb, J.
|
|
|
32 |
S3 |
p. S210
|
artikel
|
| 344 |
SO-23 The genomic temporal heterogeneity of circulating tumor DNA in metastatic colorectal cancer under first-line treatment
|
Huang, Y.
|
|
|
32 |
S3 |
p. S212
|
artikel
|
| 345 |
SO-17 The global POLAR program: Top-line results of placebo-controlled studies of calmangafodipir on top of modified FOLFOX6 to prevent chemotherapy-induced peripheral neuropathy
|
Qvortrup, C.
|
|
|
32 |
S3 |
p. S209-S210
|
artikel
|
| 346 |
SO-1 The impact of COVID-19 on daily practice patterns in the third-line setting for patients with metastatic colorectal cancer: Results of a real-world survey
|
Prager, G.
|
|
|
32 |
S3 |
p. S202
|
artikel
|
| 347 |
SO-7 The prognostic and predictive role of preoperative chemotherapy sensitivity in gastric adenocarcinoma: A study of national cancer database
|
Deng, L.
|
|
|
32 |
S3 |
p. S204-S205
|
artikel
|
| 348 |
SO-14 The prognostic impact of KRAS G12C mutation in patients with metastatic colorectal cancer: A multicenter retrospective observational study
|
Matsubara, Y.
|
|
|
32 |
S3 |
p. S208
|
artikel
|
| 349 |
SO-3 Treatment sequences and prognostic factors in metastatic pancreatic ductal adenocarcinoma: Univariate and multivariate analyses of a real-world study in Europe
|
Taieb, J.
|
|
|
32 |
S3 |
p. S203
|
artikel
|
| 350 |
SO-5 Tumor inflammation and proliferative status as biomarkers in gastroesophageal adenocarcinoma
|
Mukherjee, S.
|
|
|
32 |
S3 |
p. S204
|
artikel
|
| 351 |
SO-12 Updated safety, efficacy, and PK results from an open-label, multicenter, phase I/II study of avapritinib in Chinese patients with unresectable or metastatic gastrointestinal stromal tumors
|
Li, J.
|
|
|
32 |
S3 |
p. S207
|
artikel
|
| 352 |
Table of Contents
|
|
|
|
32 |
S3 |
p. iv
|
artikel
|
| 353 |
Title Page
|
|
|
|
32 |
S3 |
p. iii
|
artikel
|
Tijdschrift beschrijving